What does Century Therapeutics do?

Century develops allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs), engineering immune cells to target diseases with the aim of creating scalable, off-the-shelf treatments.

Why is the market capitalisation relevant?

A market cap of about $48.8m indicates a small-cap company; small caps can offer higher upside but typically come with greater volatility and higher risk, especially for early-stage biotech firms.

What are the main risks to consider?

Key risks include scientific and clinical trial failure, regulatory setbacks, manufacturing scale-up challenges, and the need for additional financing. These factors can substantially affect valuation and share price.

How can I follow the company’s progress?

Track official company announcements, regulatory filings, clinical trial registries, and reputable financial news. Events such as trial readouts, partner deals, or financing rounds tend to move the share price.

Century Therapeutics (IPSC) Stock

Early stage biotech developing off the shelf cell therapies. Here's the price, business snapshot, and what's worth knowing about Century Therapeutics in October 2026.

Century Therapeutics, Inc (ticker IPSC) is an early-stage biotechnology company developing allogeneic cell therapies using induced pluripotent stem cells (iPSCs). The company seeks to create ‘off-the-shelf’ engineered immune cells intended to treat cancer and other diseases, aiming for scalable manufacturing and potential cost advantages versus personalised approaches. With a market capitalisation around $48.8m, Century is a small-cap, typically pre-revenue business where programmes may still be preclinical or in early clinical stages. Investors should note the high scientific, regulatory and financing risks common to cell-therapy developers: clinical trials may fail, manufacturing scale-up can be challenging, and additional capital may be required. The share price can be volatile. This summary is for general educational purposes only and is not personal financial advice; investors should carry out their own research and consider their risk tolerance and investment horizon.

Sixth Month Growth Performance

$1.53

-0.78 (33.77%)past 6 months

≈

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying Century Therapeutics' stock with a target price of $8.51, indicating significant growth potential.

Average

Financial Health

Century Therapeutics is managing its finances reasonably well, with solid cash flow and book value.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

View more stocks by downloading the app for FREE

It only takes 60 seconds.

Why You’ll Want to Watch This Stock

📈

Early-stage biotech

Small market cap and early clinical programmes could offer upside if science succeeds, though outcomes are uncertain and volatility is likely.

⚡

iPSC platform potential

iPSC-derived, off-the-shelf cells aim for scalable manufacturing and broader patient reach, but technical and regulatory hurdles remain significant.

🌍

Partnerships matter

Collaborations or licences can provide funding and expertise to derisk development, yet deal terms and execution affect prospective value.

Why invest with Nemo?

🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

Frequently asked questions

Century Therapeutics (IPSC) Stock

Early stage biotech developing off the shelf cell therapies. Here's the price, business snapshot, and what's worth knowing about Century Therapeutics in October 2026.